Glaucoma as a neurodegenerative disease

Journal of Neuro-Ophthalmology

Volumn 35, Issue , 2015, Pages S22-S28

  Danesh Meyer, Helen V ^a   Levin, Leonard A ^b,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MCGILL UNIVERSITY   (Canada)

^c Department of Ophthalmology and Visual Sciences ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM;

ARTICLE; ASYMPTOMATIC DISEASE; BRAIN FUNCTION; CALCIUM HOMEOSTASIS; CELL DAMAGE; CELL POPULATION; CLINICAL FEATURE; CONCEPTUAL FRAMEWORK; DEGENERATIVE DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETIC PREDISPOSITION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NERVE CELL; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; OPTIC NERVE DISEASE; OPTIC NERVE INJURY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN MISFOLDING; RETINA DISEASE;

EID: 84975484469     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/WNO.0000000000000293     Document Type: Article

References (82)

1. Bussel II, Wollstein G, Schuman JS OCT for glaucoma diagnosis detection of glaucoma progression. Br J Ophthalmol. 2014; 98 (suppl 2):ii15-ii19.
2. Milesi M, Rocca MA, Bianch-Marzoli S, Petrolini M., Pagani E, Falini A, Comi G., Flippi M. Patterns of white matter diffusivity abnormalities in Leber's hereditary optic neuropathy: a tract-based spatial statistics study. J Neurol. 2012:259:1801-1807.
3. Rossiter JP. Trans-synaptic degeneration of lateral geniculate nuclei following remote loss of right eye. JAMA Ophthalmol. 2015; 133:e141789.
4. Hernowo AT, Prins D, Baseler H.A., Plank T., Gouws AD, Hooymans JM, Morland AB, Greenlee M.W., Cornellissen FW Morphometric analyses of the visual pathways in macular degeneration. Cortex. 2014; 56:99-110.
5. Goldby F. A note on transneuronal atrophy in the human lateral geniculate body. J Neurol Neurosurg Psychiatry. 1957; 20:202-207.
6. Matthews M. Further obhservations on transneuronal degeneration in the lateral geniculate nucleus of the macaque monkey. J Anat. 1964; 98:255-263.
7. Chaturvedi N, Hedley-Whyte ET, Dreyer EB. Lateral geniculate nucleus in glaucoma. Am J Ophthalmol. 1993; 116:182-188.
8. Chen WW, Wang N, Cai S. Structural brain abnormalities in patients with primary open-angle glaucoma: a study with 3T MR imaging. Invest Ophthalmol Vis Sci. 2013; 54:545-554.
9. Weber AJ, Chen H, Hubbard W.C., Kaufman P. Experimental glaucoma and cell size, density, and number in the primary lateral geniculate nucleus. Invest Ophthalmol Vis Sci. 2000; 41:1370-1379.
10. Gupta N, Ang LC, Noël de Tilly L, Bidaisee L, Yucel YH. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol. 2006:90;674-678.
11. Jindahra P, Petrie A, Plant GT Retrograde trans-synaptic retinalganglion cell loss identified by optical coherence tomography. Brain. 2007; 132:628-634.
12. Crawford ML, Harwerth RS, Smith E.L., Mills S., Ewing B. Experimental glaucoma in primates: changes in cytochrome oxidase blobs in V1 cortex. Invest Ophthalmol Vis Sci. 2001; 42:358-364.
13. Gupta N, Ly T, Zhang W., Kaufman PL, Weinreb RN, Yucel YH. Chronic ocular hypertension induces dendrite pathology in the lateral geniculatge nucleus of the brfain. Exp Eye Res. 2007; 84:L176-L184.
14. Crish SD, Sappington RM, Inman D.M., Horner PJ, Calkins DJ. Distal axonopathy with structural persistence in glaucomatous neurodegeneration. Proc Natl Acad Sci U S A. 2010; 107:5196-5201.
15. Chen Z, Lin F, Wang J., Li Z, Dai H, Muk GeJ, Zhang H. Diffusion tensor magnetic resonance imaging reveals visual pathway damage that correlates with clinical severity in glaucoma. Clin Exp Ophthalmol. 2013; 41:43-49.
16. Dai H, Mu KT, Qi J.P., Wang CY, Zhu WZ, Xia LM, Chen Z.Q., Zhang H., Ai F, Morelli JN Assessment of lateral geniculate nucleus atrophy with 3T MR imaging and correlation with clinical stage of glaucoma. AJNR Am J Neuroradiol. 2011; 32:1347-1353.
17. Ong K, Farinelli A, Billson F., Houang M, Stern M. Comparative study of brain magnetic resonance imaging findings in patients with low-tension glaucoma and control subjects. Ophthalmology. 1995; 102:1632-1638.
18. Stroman GA, Stewart WC, Golnik K.C., Cure JC, Olinger RE. Magnetic resonance imaging in patients with low-tension glaucoma. Arch Ophthalmol. 1995; 113:168-172.
19. Suzuki J, Tomidokoro A, Araie M., Tomita G, Yamagami J, Okubo T., Masumoto T. Visual field damage in normal-tension glaucoma patients with or without ischemic changes in cerebral magnetic resonance imaging. Jpn J Ophthalmol. 2004; 48:340-344.
20. Sugiyama T, Utsunomiya K, Ota H., Ogura Y, Narabayashi I, Ikeda T. Comparative study of cerebral blood flow in patients with normal-tension glaucoma and control subjects. Am J Ophthalmol. 2006; 141:394-396.
21. Harris A, Siesky B, Zarfati D., Haine CL, Catoira Y, Sines DT, McCranor L, Garzozi HJ Relationship of cerebral blood flow and central visual function in primary open-angle glaucoma. J Glaucoma. 2007; 16:159-163.
22. Kitsos G, Zikou AK, Bagli E, Kosta P., Argyropoulou MI. Conventional MRI and magnetisation transfer imaging of the brain and optic pathway in primary open-angle glaucoma. Br J Radiol. 2009; 82:896-900.
23. Harris A, Zarfati D, Zalish M., Biller J, Sheets CW, Rechtman E, Mimgliardi R., Garzozi HJ Reduced cerebrovascular blood flow velocities and vasoreactivity in open-angle glaucoma. Am J Ophthalmol. 2003; 135:144-147.
24. Akarsu C, Bilgili YK, Unal B, Taner P., Ergin A, Kara SA. Cerebral hemodynamics in ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2005; 243:317-320.
25. Williams AL, Lackey J, Wizov S.S., Chia TMT, Gatla S, Moster M., Sergott R, Spaeth GL, Lai S. Evidence for widespread structural brain changes in glaucoma: a preliminary voxel-based MRI study. Invest Ophthalmol Vis Sci. 2013; 54:5880-5887.
26. Zikou AK, Kitsos G, Tzarouchi L.C., Astrakas L., Alexiou GA, Argyropoulou MI. Voxel-based morphometry and diffusion tensor imaging of the optic pathway in primary open-angle glaucoma: a preliminary study. Am J Neuroradiol. 2012; 33:128-134.
27. Yucel YH, Zhang Q, Gupta N., Kaufman PL, Weinreb RN. Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch Ophthalmol. 2000; 118:378-384.
28. Yucel YH, Zhang Q, Weinreb R.N., Kaufman PL, Gupta N. Atrophy of relay neurons in magno- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest Ophthalmol Vis Sci. 2001; 42:3216-3222.
29. Gupta N, Yucel YH Brain changes in glaucoma. Eur J Ophthalmol. 2003; 13 (suppl 3):S32-S35.
30. Gupta N, Greenberg G, de Tilly LN, Gray B, Polemidiotis M, Yucel YG Atrophy of the lateral geniculate nucleus in human glaucoma detected by magnetic resonance imaging. Br J Ophthalmol. 2009; 93:56-60.
31. Boucard CC, Hernowo AT, Magurie R.P., Jasonius NM, Roerdink JB, Hooymans JM, Cornelissan FW Changes in cortical grey matter density associated with long-standing retinal visual field defects. Brain. 2009; 32:1898-1919.
32. Broman AT, Quigley HA, West S.K., Katz J., Munoz B, Bandeen-Roche K, Tielsch JM, Friedman D.S., Crowsten J., Taylor HR, Varma R, Leske MC, Bengtsson B, Heijl A., He M, Foster PJ. Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. Invest Ophthalmol Vis Sci. 2008; 49:66-76.
33. McKinnon SJ. The cell and molecular biology of glaucoma: common neurodegenerative pathways and relevance to glaucoma. Invest Ophthalmol Vis Sci. 2012; 53:2485-2487.
34. Yu-Wai-Man P. Mitochondrial dysfunction in glaucoma: closing the loop. Invest Ophthalmol Vis Sci. 2012; 53:2438.
35. Hattenhauer MG, Johnson DH, Ing H.H., Herman DC, Hodge DO, Yawn BP, Butterfield L.C., Gray DT The probability of blindness from open-angle glaucoma. Ophthalmology. 1998; 105:2099-2104.
36. Kingwell K. Alzheimer disease: Alzheimer disease biomarkers in healthy individuals can predict cognitive decline several years later. Nat Rev Neurol. 2013; 9:300.
37. Shapira AHV, Olanow CW Neuroprotection in Parkinson's disease: mysteries, myths, and misconceptions. JAMA. 2004; 291:358-364.
38. Khan AO. Genetics of primary open angle glaucoma. Curr Opin Ophthalmol. 2011; 22:347-355.
39. Janssen SF, Gorgels TG, Ramdas W.D., Klaver CC, van Dujin CM, Jansonius NM, Bergen AA The vast complexity of primary open angle glaucoma: disease genese, risks, molecular mechanisms and pathology. Prog Retin Eye Res. 2013; 37:31-67.
40. Hoozemans JJ, Veerehuis R, Rozemuller J.M., Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci. 2005; 24:157-165.
41. Schuitemaker A, Dik MG, Veerhuis R, Scbeltens P., Schoonenboom NS, Hack CE, Blankenstein MA, Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging. 2009; 30:1885-1889.
42. McGeer EG, McGeer PL Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv. 2001; 1:22-29.
43. McGeer PL, McGeer EG Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord. 2010; 10 (suppl 1):S3-S7.
44. Jakobs TC, Libby RT, Ben Y, John SWM, Masland RH. Retinal ganglion cell degeneration is topological but not cell type specific in DBA/2J mice. J Cell Biol. 2005; 171:313-325.
45. Schlamp CL, Li Y, Dietz J.A., Janssen KT, Nickells RW. Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC Neurosci. 2006; 7:66.
46. Quigley HA. Glaucoma. Lancet. 2011; 377:1367-1377.
47. Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr Opin Pharmacol. 2013; 13:23-31.
48. Nickells RW, Howell GR, Soto I, John SW Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu Rev Neurosci. 2012; 35:153-179.
49. Hernandez MR, Miao H, Lukas T. Astrocytes in glaucomatous optic neuropathy. Prog Brain Res. 2008; 173:353-373.
50. Nikolskaya T, Nikolsky Y, Serebryiskaya T., Zvereva S, Sviordov E, Dezso Z., Rahkmatulin E, Brennan RJ, Yankovsky N, Bhattacharya K., Agapova O, Hernandez MA, Shestopalov VI Network analysis of human glaucomatous optic nerve head astrocytes. BMC Med Genomics. 2009; 2:24.
51. Szentirmai O, Carter BS Genetic and cellular therapies for cerebral infarction. Neurosurgery. 2004; 55:283-286.
52. Fitch MT, Doller C, Combs C.K., Landreth GE, Silver J. Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J Neurosci. 1999; 19:8182-8198.
53. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta. 1998; 1366:211-223.
54. Beal BF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 1993; 16:125-131.
55. Zanon-Moreno V., Marco-Ventura P, Lleo-Perez A, Pons-Vazquez S, Garcia-Medina JJ, Vinuesa-Silva I, Mareno-Nadal MA, Pinazo-Duran MD. Oxidative stress in primary open-angle glaucoma. J Glaucoma. 2008; 17:263-268.
56. Osborne NN, Casson RJ, Wood J.P., Chidlow G., Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res. 2004; 23:91-147.
57. Neufeld AH. Microglia in the optic nerve head and the region of parapapillary chorioretinal atrophy in glaucoma. Arch Ophthalmol. 1999; 117:1050-1056.
58. Mehdizadeh M. Oxidative stress and open angle glaucoma: is oxidative stress a mechanism for glaucomatous damage or a by-product of topical antiglaucoma medication? J Glaucoma. 2008; 17:505.
59. Chrysostomou V, Rezania F, Trounce I.A., Crowston JG. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol. 2013; 13:12-15.
60. Lin MT, Beal MF Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases, Nature. 2006; 443:787-795.
61. Mizuno Y, Ikebe SI, Hattori N, Nakagawa-Hattori Y, Mochizuki H., Tanaka M, Ozawa T. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim Biophys Acta. 1995; 1271:265-274.
62. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res. 2006; 25:490-513.
63. Kanamori A, Catrinescu MM, Kanamori N, Mears K.A., Beaubien R., Levin LA. Superoxide is an associated signal for apoptosis in axonal injury. Brain. 2010; 133:2612-2625.
64. Almasieh M, Lieven CJ, Levin L.A., Di Polo A. A cell-permeable phosphine-borane complex delays retinal ganglion cell death after axonal injury through activation of the pro-survival extracellular signal-regulated kinases 1/2 pathway. J Neurochem. 2011; 118:1075-1086.
65. Crish SD, Calkins DJ Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms. Neuroscience. 2011; 176:1-11.
66. Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous system. Nature. 2006; 443:796-802.
67. Kawahara M, Kuroda Y. Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res Bull. 2000; 53:389-397.
68. Huang W, Fileta J, Rawe I., Qu J, Grosskreutz CL. Calpain activation in experimental glaucoma. Invest Ophthalmol Vis Sci. 2008; 51:3049-3054.
69. Gupta N, Yucel Y. Glaucoma as a neurodegenerative disease. Curr Opin Ophthalmol. 2007; 18:110-114.
70. Calkins DJ. Critical pathogenic events underlying progression of neurodegeneration in glacuoma. Prog Retin Eye Res. 2012; 31:702-719.
71. Spires-Jones T.L., Stoothoff WH, de Calignon A, Jones PB, Hyman BT Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009; 32:150-159.
72. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009; 118:167-179.
73. Kipfer-Kauer A., McKinnon SJ, Frueh B.E., Goldblum D. Distribution of amyloid precursor protein and amyloid-beta in ocular hypertensive C57BL/6 mouse eyes. Curr Eye Res. 2010; 35:828-834.
74. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges C.A., Pease ME, Kerrigan DF, Ransom NL, Tahzib N.G., Reitsamer HA, Levkovitch-Verbin H, Quigley HA, Zack DJ Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002; 43:1077-1087.
75. Nguyen JV, Soto I, Kim K.Y., Bushong EA, Oglesby E, Valiente-Soriano FJ, Yang Z, Davis C.H., Bedont JL, Son JL, Wei JO, Buchman V.L., Zack DJ, Vidal-Sanz M, Ellsman MH, Marsh-Armstrong N. Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc Natl Acad Sci U S A. 2011; 108:1176-1181.
76. Gupta N, Fong J, Ang L.C., Yucel YH. Retinal tau pathology in human glaucomas. Can J Ophthalmol. 2008; 43:53-60.
77. Hardy J, Revesz T. The spread of neurodegenerative diseases. N Engl J Med. 2012; 366:2126-2128.
78. Nalivaeva NN, Belyaev N, Kerridge C., Turner AJ. Amyloid-clearing proteins and their epigenic regulation as therapeutic target in Alzheimer's disase. Front Aging Neurosci. 2014; 6:235.
79. Ebrahimi-Fakhari D., McLean PJ, Unni VK Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy. 2012; 8:281-283.
80. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007; 8:519-529.
81. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol. 1989; 107:186-188.
82. Garway-Heath D.F., Crabb DP, Bunce C, Lascaratos G., Amalfitano F, Anand N, Azvara-Bianco A, Bourne R.R., Broadway DC, Cunliffe IA, Diamond JP, Fraser F.G., Ho TA, Martin KR, McNaught AI, Negi A, Patel K., Russell RA, Shah A, Spry PG, Suzuki K, White E.T., Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomized, multicentre, placebo-controlled trial. Lancet. 2015; 385:1295-1304.